Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to -$12.8 million.

  • Akebia Therapeutics' Change in Accured Expenses rose 606.21% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 383.23%. This contributed to the annual value of -$12.8 million for FY2024, which is 27.50% down from last year.
  • As of FY2024, Akebia Therapeutics' Change in Accured Expenses stood at -$12.8 million, which was down 27.50% from -$10.0 million recorded in FY2023.
  • Akebia Therapeutics' Change in Accured Expenses' 5-year high stood at $6.3 million during FY2020, with a 5-year trough of -$38.0 million in FY2022.
  • Its 3-year average for Change in Accured Expenses is -$20.3 million, with a median of -$12.8 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Change in Accured Expenses surged by 122.88% in 2020 and then tumbled by 452.77% in 2021.
  • Over the past 5 years, Akebia Therapeutics' Change in Accured Expenses (Yearly) stood at $6.3 million in 2020, then tumbled by 452.77% to -$22.1 million in 2021, then crashed by 72.12% to -$38.0 million in 2022, then surged by 73.63% to -$10.0 million in 2023, then declined by 27.50% to -$12.8 million in 2024.